Uniunea Europeană - română - EMA (European Medicines Agency)

krka, d.d., novo mesto  - lenalidomide hydrochloride monohydrate - multiple myeloma; lymphoma, follicular - imunosupresoare - multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) este indicat pentru tratamentul pacienților adulți cu mielom multiplu netratați anterior, care nu sunt eligibili pentru transplant. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) este indicat pentru tratamentul pacienților adulți cu mielom multiplu netratați anterior, care nu sunt eligibili pentru transplant. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

meda pharma gmbh & co. kg - formoterolum - pulb. de inhal. - 6micrograme/doza - adrenergice inhalante agonisti selectivi ai receptorilor beta 2 adrenergici

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

meda pharma gmbh & co. kg - formoterolum - pulb. de inhal. - 12micrograme/doza - adrenergice inhalante agonisti selectivi ai receptorilor beta 2 adrenergici

Uniunea Europeană - română - EMA (European Medicines Agency)

taw pharma (ireland) limited - clopidogrel clorhidrat - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - agenți antitrombotici - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

upm din borisov sad - procainum - solutie injectabila - 5 mg/ml

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

synthon hispania, s.l. - spania - abirateronum - compr. - 250mg - antagonisti hormonali si substante inrudite alti antagonisti hormonali si substante inrudite

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

synthon hispania, s.l. - spania - abirateronum - compr. film. - 500mg - antagonisti hormonali si substante inrudite alti antagonisti hormonali si substante inrudite

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

novo nordisk a/s - danemarca - insulina umane - susp. inj. in stilou injector preumplut - 100ui/ml - insuline si analogi insuline si analogi act. interm. comb.cu act. rapida, inject

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

novo nordisk a/s - danemarca - insulina umane - susp. inj. in stilou injector preumplut - 100ui/ml - insuline si analogi insuline si analogi act. interm. comb.cu act. rapida, inject

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

novo nordisk a/s - danemarca - insulina umane - susp. inj. in stilou injector preumplut - 100ui/ml - insuline si analogi insuline si analogi act. interm. comb.cu act. rapida, inject